TSXV:BTI.H - Post by User
Post by
Sir_Holleron Aug 03, 2015 10:50am
204 Views
Post# 23984613
Antibody data
Antibody dataThis data is what is driving excitement...
The Medimmune data.
~
Up to 5% of the injected dose of the MTfp-antibody fusion entered the brain and showed peak transport at 24 hours. Active transport into the brain of between 3-4% continued for more than 12 days. In contrast, the full-length MTf-antibody fusion showed a peak of brain exposure at approximatively 2 hrs, which decreased afterwards, exhibiting a half-life in plasma of 5 days. Importantly, administration of either MTf-antibody or MTfp-antibody fusion or conjugate produced a greater degree of analgesia in the neuropathic pain model when compared to administration of the antibody alone. Analgesia is dependent on the antibody entering the CNS.
Stated CEO Rob Hutchison, "These results with MedImmune are of great importance for biOasis and its licensing business model. We now know that the MTfp amino acid sequence can be provided to a licensee and the licensee will be able to build the sequence into its therapeutics with relative ease and with low manufacturing costs. In addition, the increased half-life observed with the MTfp transport vector results in a much higher exposure of the therapeutic in the brain, a key consideration for our potential licensing partners."
Read more at https://www.stockhouse.com/news/press-releases/2015/05/12/bioasis-provides-scientific-updates-on-its-transcend-programs#uQGL04wZUrDTdBBb.99